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Introduction
P-glycoprotein (P-gp) acts at the blood-brain barrier
(BBB) as an active cell membrane efflux pump for several
endogenous and exogenous compounds. The P-gp sub-
strate (R)-[11C]verapamil (VPM) can be used to measure
P-gp-mediated transport at the BBB in vivo with positron
emission tomography (PET). The distribution volume
(DV) of VPM has been shown to inversely reflect P-gp
function in the BBB [1].
Materials and methods
A young (n = 7, mean age: 28.0 ± 3.8 years) and an aged
group (n = 6, mean age: 69.4 ± 8.5 years) of healthy vol-
unteers underwent dynamic VPM PET scans and arterial
blood sampling. Radiolabelled metabolites of VPM were
quantified by a previously described combined solid-
phase extraction/HPLC protocol [1]. A whole-brain grey
matter region was defined by using the Hammersmith
n20r49 brain atlas [2]. The DV of VPM was estimated by
using a 2-rate-constant-1-tissue-compartment model [1].
Results
Mean DVs (± standard deviation) of VPM were 0.50 ± 0.08
for the young and 0.63 ± 0.13 for the aged group (+27%
for the aged group, p = 0.04, 2-tailed t-test). There was no
significant difference in VPM metabolism between the
young and the aged group (area under the curve of the
fraction of polar [11C]metabolites of VPM versus time in
arterial plasma: 12.7 ± 2.4 and 14.1 ± 3.6 for the young
and the aged group, respectively, p = 0.19, 2-tailed t-test).
Conclusion
Our data confirm previous results that older subjects show
significantly decreased P-gp function in the BBB [1,3].
Decreased P-gp function can lead to increased accumula-
tion of toxins and drugs in the aging brain and could thus
be a risk factor for the development of neurodegenerative
disease.
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